Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro by Huang, Qiang et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Glioma stem cells are more aggressive in recurrent tumors with 
malignant progression than in the primary tumor, and both can be 
maintained long-term in vitro
Qiang Huang1, Quan-Bin Zhang2, Jun Dong*1, Yin-Yan Wu1, Yun-
Tian Shen3, Yao-Dong Zhao1, Yu-De Zhu1, Yi Diao1, Ai-Dong Wang1 and 
Qing Lan1
Address: 1Department of Neurosurgery and Brain Tumor Research Laboratory, the Second Affiliated Hospital of Suzhou University, Suzhou 
215004, PR China, 2Department of Neurosurgery, Kowloon Hospital, Shanghai Jiaotong University Medical School, Suzhou 215021, PR China 
and 3Departments of Radiation Oncology, the Second Affiliated Hospital of Suzhou University, Suzhou 215004, PR China
Email: Qiang Huang - hq1936@yahoo.com.cn; Quan-Bin Zhang - quanbinzhang@yahoo.com.cn; Jun Dong* - djdongjun@163.com; Yin-
Yan Wu - wchywyy@yahoo.com.cn; Yun-Tian Shen - shenyuntian2001@yahoo.com.cn; Yao-Dong Zhao - dm0920@gmail.com; Yu-
De Zhu - zyddzy2000@yahoo.com.cn; Yi Diao - dpdy118@yahoo.com.cn; Ai-Dong Wang - eagle.wangad@yahoo.com.cn; 
Qing Lan - szlq006@yahoo.com.cn
* Corresponding author    
Abstract
Background: Despite the advances made during decades of research, the mechanisms by which
glioma is initiated and established remain elusive. The discovery of glioma stem cells (GSCs) may
help to elucidate the processes of gliomagenesis with respect to their phenotype, differentiation
and tumorigenic capacity during initiation and progression. Research on GSCs is still in its infancy,
so no definitive conclusions about their role can yet be drawn. To understand the biology of GSCs
fully, it is highly desirable to establish permanent and biologically stable GSC lines.
Methods: In the current study, GSCs were isolated from surgical specimens of primary and
recurrent glioma in a patient whose malignancy had progressed during the previous six months.
The GSCs were cryopreserved and resuscitated periodically during long-term maintenance to
establish glioma stem/progenitor cell (GSPC) lines, which were characterized by
immunofluorescence, flow cytometry and transmission electronic microscopy. The primary and
recurrent GSPC lines were also compared in terms of in vivo tumorigenicity and invasiveness.
Molecular genetic differences between the two lines were identified by array-based comparative
genomic hybridization and further validated by real-time PCR.
Results: Two GSPC lines, SU-1 (primary) and SU-2 (recurrent), were maintained in vitro for more
than 44 months and 38 months respectively. Generally, the potentials for proliferation, self-renewal
and multi-differentiation remained relatively stable even after a prolonged series of alternating
episodes of cryopreservation and resuscitation. Intracranial transplantation of SU-1 cells produced
relatively less invasive tumor mass in athymic nude mice, while SU-2 cells led to much more diffuse
and aggressive lesions strikingly recapitulated their original tumors. Neither SU-1 nor SU-2 cells
reached the terminal differentiation stage under conditions that would induce terminal
differentiation in neural stem cells. The differentiation of most of the tumor cells seemed to be
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blocked at the progenitor cell phase: most of them expressed nestin but only a few co-expressed
differentiation markers. Transmission electron microscopy showed that GSCs were at a primitive
stage of differentiation with low autophagic activity. Array-based comparative genomic
hybridization revealed genetic alterations common to both SU-1 and SU-2, including amplification
of the oncogene EGFR and deletion of the tumor suppressor PTEN, while some genetic alterations
such as amplification of MTA1 (metastasis associated gene 1) only occurred in SU-2.
Conclusion: The GSPC lines SU-1 and SU-2 faithfully retained the characteristics of their original
tumors and provide a reliable resource for investigating the mechanisms of formation and
recurrence of human gliomas with progressive malignancy. Such investigations may eventually have
major impacts on the understanding and treatment of gliomas.
Background
Recent decades have seen only limited progress in treat-
ment trials and basic research on human glioma, the most
common central nervous malignancy. This is partly
because previously-established glioma cell lines are com-
posed of morphologically and functionally diverse cells
that express a variety of neural lineage markers [1]. It is
now generally accepted that these previously-established
serum-based cell lines do not replicate the major biologi-
cal features, particularly the stem cells, of human cancers.
Therefore, there is an urgent need for new and clinically
relevant in vitro model systems for studying tumor biology
and conducting preclinical screening of drugs for malig-
nant brain tumors.
There is overwhelming evidence that glioma tissue con-
tains stem cells that are broadly similar to neural stem
cells but differ from them in important ways [2-5].
Although CD133, a 120 kDa cell-surface marker of nor-
mal human neural stem cells (NSCs), is not a specific
marker or gold standard for identifying glioma stem cells,
it has been used in most relevant studies for enriching
tumor stem-like cells from brain tumors. Vescovi offered
a functional definition of brain tumor stem cells, namely:
brain tumor cells should qualify as stem cells if they show
cancer-initiating ability upon orthotopic implantation,
extensive self-renewal ability demonstrated either ex vivo
or in vivo, karyotypic or genetic alterations, aberrant dif-
ferentiation properties, capacity to generate non-tumori-
genic end cells, and multilineage differentiation capacity
[6]. Because this subpopulation of glioma cells, generally
called glioma stem cells (GSCs), may play an extremely
critical role in the initiation and recurrence of gliomas,
studies focusing on GSCs have been promoted rapidly.
However, conclusions about the biological features of
GSCs are not always consistent and sometimes even con-
fusing [1,7-14]. Most investigators believe that short-term
cultured stem cells are superior to those maintained long-
term. However, since glioma tissues are in very short sup-
ply, it is difficult to find tumor stem cells readily for either
biological or preclinical drug studies. Therefore, perma-
nent GSC lines could serve such purposes better than
GSCs maintained short-term.
Tumor recurrence is the primary cause of treatment failure
and death in glioma patients. Although cancer stem cells
are now widely believed to be responsible for tumor recur-
rence, we do not know whether such cells are exactly the
same in recurrent tumors as in the primary tumor in cases
of malignancy progression.
We have isolated GSCs from surgical specimens of both
primary and recurrent gliomas in recent years. Fortu-
nately, GSCs from primary and recurrent tumors in the
same patient were screened out and could be maintained
long-term [15]. In the current study, we describe the
results of long-term (more than three years) in vitro
growth of these GSCs and their detailed characterization.
To ensure that GSCs are available for use when required,
the cells were periodically cryopreserved and resuscitated
during long-term culture and tested for their capacity to
form new nonadherent tumor spheres upon retrieval. We
also compared the biological characteristics of GSCs
derived from the primary and recurrent tumors in a
patient with malignancy progression.
Methods
Clinical Information
Our studies were approved by the Medical Review Board
of Suzhou University Medical School. Signed informed
consent was obtained from the patients or their legal
guardians prior to sample acquisition. Fresh surgical spec-
imens were obtained from a 52-year-old female patient
who had undergone two operations with an interval of 6
months because of the rapid re-growth of tumor mass in
the right temporal lobe. The patient had received one dose
of radiotherapy (45 Gy) one month after the initial sur-
gery, then three doses of chemotherapy (VM26 0.1 ivgtt ×
3 days followed by MeCCNU 200 mg PO once) at one-
month intervals. In recurrence, a new solitary focus
emerged in the ipisilateral frontal lobe in addition to
tumor re-growth in situ. The primary lesion was patholog-BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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ically diagnosed as mixed glioma comprising anaplastic
ependymoma and astrocytoma (WHO grade III), while
the recurrent lesion had transformed and progressed into
glioblastoma multiforme (WHO grade IV) (Fig. 1) despite
the continuous post-surgical radiotherapy and chemo-
therapy.
Isolation and culture of glioma stem cells
Tumor tissues were washed and minced with fine scissors
into small fragments. Single tumor cells and small clumps
(3–5 cells per clump) were collected with a 35 μm cell
strainer, then resuspended in DMEM-F-12 culture
medium (Gibco-Invitrogen) to achieve a final concentra-
tion of 1 × 108 live cells per ml as assessed by Trypan blue
staining [16]. Tumor spheres were cultured as described
previously with some modifications [15].
Flow cytometry and FACS of CD133-positive cells
A single cell-suspension from the tumor spheres was centri-
fuged, and magnetic cell separation and fluorescence-acti-
vated cell sorting were performed as follows. The cells were
dissociated and resuspended in PBS. For magnetic labeling,
CD133/1 Micro Beads were used (Miltenyi Biotech). Positive
magnetic cell separation (MACS) was carried out using sev-
eral MACS columns in series according to the manufacturer's
instructions (Miltenyi Biotec). Cells were labeled with phyco-
erythin (PE)-conjugated monoclonal antibodies against
human CD133 (CD133/2-PE, Miltenyi Biotec) or isotype
control antibody (IgG2b(mouse)-PE, Caltag Laboratories)
and analyzed using a BD FACS Calibur. The isolated CD133+
cells were suspended in defined stem cell growth medium
containing DMEM-F-12, N2 supplement (Gibco), penicillin
G, streptomycin sulfate, recombinant human FGF-2 (20 ng/
ml; R&D System) and recombinant human EGF (20 ng/ml;
R&D Systems), and were plated at a density of 2 × 106 live
cells per 75 cm2 on an uncoated plastic flask.
Aliquots of CD133+ tumor cells obtained from MACS
were further flow-sorted by FACS. The cells were labeled
with CD133/2-PE at 4°C for 10 min following the manu-
facturer's instructions, then washed and resuspended in
stem cell growth medium; negative controls were per-
formed with IgG2b(mouse)-PE antibody as recom-
mended by the manufacturer. The cells were then flow-
sorted and dead cells were excluded by propidium iodide
(PI) staining.
Subsphere formation
Tumor spheres of different passages were dissociated into
single cells and plated at a density of one cell per well.
Half the volume of each culture medium (50 μl) was
changed every three days. The formation of tumor spheres
was observed under a phase-contrast microscope.
Proliferation
For proliferation assays, cells were plated on 96-well
plates and cultured in 200 μl stem cell growth medium/
well at a density of 2000 cells/ml. From day 0 to day 10
after plating, viable cells were quantified using the 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-
based Colorimetric Assay Cell Proliferation kit (Roche)
according to the manufacturer's instructions.
Tumor spheres cultured alternately in serum-based 
medium and serum-free stem cell growth medium
Nonadherent tumor spheres were seeded into DMEM-F12
medium supplemented with 10% fetal bovine serum
(FBS, Hyclone). After the spheres had attached to the bot-
tom of the flask and grown into cell monolayers for two
weeks, the cells were washed with PBS to remove fetal
bovine serum and transferred to defined stem cell growth
medium. These procedures were repeated and morpho-
logical changes in the tumor cells were observed under a
phase-contrast microscope.
MRI images of a 52-year-old female patient who underwent two operations with an interval of 6 months because of the rapid  relapse of her tumor Figure 1
MRI images of a 52-year-old female patient who underwent two operations with an interval of 6 months 
because of the rapid relapse of her tumor. A, The primary tumor located in the right temporal lobe and pathologically 
diagnosed as mixed glioma composed of anaplastic ependymoma and astrocytoma (WHO grade III). B, Post-operation image 
showing nearly total resection of the tumor. C, D, Relapse occurring 6 months later in situ and the ipsilateral frontal lobe; the 
recurrent lesion had transformed and progressed into glioblastoma multiforme (WHO grade IV).BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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Immunofluoresence staining to detect the expression of 
differentiation markers
Isolated CD133+ cells were cultured in the aforemen-
tioned stem cell growth medium to allow tumor spheres
to form. To determine the capacity of CD133+ cells for
multi-lineage differentiation, the tumor spheres were
transferred to poly-D-lysine coated chamber slides and
cultured in DMEM-F12 supplemented with 10% FBS. For
immunofluorescence staining at different times during
differentiation, namely days 0 (cultured for 4 h in serum-
based medium), 3, 7 and 10, cells grown on the slides
were fixed with 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100. The slides were then probed with
mouse antibodies against human CD133, nestin (BD Bio-
science), GFAP (Santa Cruz) and β-Tubulin-III (BD Bio-
science). The secondary antibodies were either FITC- or
Texas Red-conjugated anti-mouse IgG (Vector Laborato-
ries). The cells were counterstained with 4',6'-diamidino-
2-phenylindole (DAPI; Vector Labs). Expression and/or
coexpression of the aforementioned cell surface markers
during differentiation was detected with a laser scanning
confocal microscope (Carl Zeiss), and images were cap-
tured on a color CCD at specific magnifications.
Tumorigenicity of GSCs
Tumor cells from both SU-1 and SU-2 spheres were col-
lected and suspended in 2 μl PBS, then injected intracra-
nially into the right caudate nucleus of athymic (NCR nu/
nu) mice. All procedures were conducted in accordance
with Chinese laws governing animal care. Briefly, under
the guidance of a stereotactic system, 2 μl cell suspension
(1 × 108 cells/ml) in PBS were delivered into the right cau-
date nucleus (0.2 μl/min) by injection through a glass
electrode connected to a Hamilton syringe. Mice were sac-
rificed when they became moribund or showed signs of
obvious neurological deficit. Tumor samples were snap-
frozen and frozen sections (10 μm) were stained with HE
following standard protocols.
Transmission electron microscopy
A single cell suspension from the tumor spheres was cen-
trifuged, and magnetic cell separation and fluorescence-
activated cell sorting were performed to collect CD133+
GSCs. Positive cells were resuspended in PBS and the sus-
pension was fixed in 4% buffered glutaraldehyde, dehy-
drated through a graded ethanol series, embedded in
Epon and cut into thin sections. The samples were imaged
by a transmission electron microscope.
Array-based comparative genomic hybridization (array-
CGH)
Genome-wide array comparative genomic hybridization
was performed to determine changes in the copy number
of genomic DNA from SU-1 and SU-2 GSCs. The array
used in this study consisted of 2632 human BACs (Spec-
tral Genomics, Houston, TX) spaced at approximately 1
megabase (Mb) intervals across the whole genome. The
experiments were performed according to the manufac-
turer's protocol, as described previously [17]. Briefly, the
arrays were pre-hybridized with human Cot-I DNA
(Gibco Invitrogen, Carlsbad, CA) and salmon testis DNA
to block the repetitive sequences on BACs. One micro-
gram of normal DNA (reference) or tumor DNA (test) was
labeled with cy5-dUTP and cy3-dUTP by random prim-
ing. To avoid dye bias, we performed dye swap experi-
ments for each sample. The probe mixture was dissolved
in hybridization mixture, denatured, cooled and mounted
with a 22 × 60 mm coverslip. Hybridizations were per-
formed in sealed chambers for 16–20 h at 60°C. After
post-hybridization washes, the arrays were scanned into
two 16-bit TIFF image files using a GenePix 4000A two-
color fluorescent scanner and quantified using GenePix
software (Axon Instruments, Union City, CA). Data were
analyzed using SpectralWare 2.2.23 (Spectral Genomics,
Houston, TX).
Quantitative real-time PCR
Real-time PCR was performed using SYBR green reagent
and the ABI PRISM 7000 Sequence Detection System (PE
Applied Biosystems) according to the manufacturer's
instructions. β-actin transcripts were quantified in all sam-
ples as an internal control for the amount and quality of
cDNA. Detailed information about primer sequence and
product size is available upon request. The primer sets
were all optimized to generate a single specific band only
from cDNA on argarose gels. Melting-curve analysis was
performed for all the reactions to control for the specifi-
city of amplifications. The results of real-time PCR were
analyzed by the ΔΔCt method and presented as the ratio
between the selected genes and β-actin  transcripts. The
selected gene/β-actin  ratio was then normalized to the
mean ratio of the selected genes in normal peripheral
blood (for DNA) or in cultured normal human astrocytes
(Cambrex, East Rutherford, NJ) (for mRNA) to calculate
the Tumor/Normal ratio. All experiments were performed
in triplicate.
Results
Growth and differentiation of GSCs maintained long-term 
in vitro
Glioma stem/progenitor (GSPC) cell lines, named SU-1
for the primary tumor and SU-2 for the recurrent tumor
associated with malignancy progression, were maintained
in vitro for more than 44 months and 38 months, respec-
tively. Both lines contained an obvious CD133+ subpop-
ulation that displayed neurosphere-like tumor spheres,
nonadherent growth and asymmetrical cell divisions
yielding cells that expressed markers of neuron and glia
differentiation. The expression and coexpression of differ-
entiation-related surface makers were examined by laserBMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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scanning confocal microscopy. Within a single sphere
grown from one CD133+ GSC, the cells expressed markers
of different neural lineages at constant proportions; most
of the tumor cells did not differentiate terminally and
often co-expressed differentiation markers with the stem/
progenitor cell marker nestin. Over 90% of the cells in
both SU-1 and SU-2 tumor spheres were nestin positive
(Fig. 2A) and about 5–10% stained positively for CD133
(Fig. 2B). When the tumor spheres became adherent mon-
olayers, one week after FBS-induced differentiation with-
out growth factor supplementation in vitro, about 78–
83% of the cells were still nestin positive (Fig. 2D, 2G).
However, about 17–22% of these nestin+ cells were also
positive for such differentiation markers as GFAP for
astroglial cells (Fig. 2E) and/or β-tubulin-III for neurons
(Fig. 2H), confirming that they retained multi-lineage dif-
ferentiation capabilities. Therefore, GSCs cannot reach the
stage of complete terminal differentiation under condi-
Expression of cell surface markers of tumor spheres before and after differentiation (×400) Figure 2
Expression of cell surface markers of tumor spheres before and after differentiation (×400). A-C, tumor spheres 
before differentiation. D-I, one week after FBS-induced differentiation. A, D, G, immunofluorescence staining for nestin 
(green). B, immunofluorescence staining for CD133 (red). E, immunofluorescence staining for GFAP (red). H, immunofluores-
cence staining for β-tubulin-III (red). C, F, I, confocol microscopy showed co-expression of nestin with CD133, GFAP and β-
tubulin-III, respectively.BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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tions that would induce terminal differentiation in NSCs.
In vitro data suggest that the differentiation of most GSCs
is blocked at the neural progenitor stage, as indicated by
the expression of nestin, or at the early stage of tumor pro-
genitor cell differentiation, as indicated by the partial co-
expression of nestin and glial/neural differentiation mark-
ers.
Nonadherent tumor spheres were dissociated and mag-
netically sorted into CD133+ and CD133- cells. Upon
replating at one cell per well, tumor spheres formed from
single CD133+ cells, often reaching a size of 30–40 cells
in approximately two weeks. Only a small proportion
(4.5% for SU-1 and 12.8% for SU-2) of the CD133+
tumor cells formed spheres, but no in vitro sphere forma-
tion was observed with CD133- cells. Sequential minimal
dilution assays for three passages confirmed that the
CD133+ single cell-derived tumor spheres had the poten-
tial to grow indefinitely. The proportion of sphere-form-
ing cells remained stable throughout the course of culture,
indicating asymmetrical cell divisions. Periodically, the
tumor sphere cells were cryopreserved and resuscitated;
the resuscitation rate was about 75%. However, SU-1 and
SU-2 showed some morphological differences in vitro.
Briefly, when cultivated in defined stem cell growth
medium (FBS free), the SU-1 tumor spheres were more
compact while the SU-2 ones seemed a little looser and
were not evenly round (Fig. 3A, 3D). When cultured in
medium containing 10% FBS, both SU-1 and SU-2 cells
changed morphologically from rolling spheres to adher-
ent monolayers. Most of the differentiated SU-1 cells were
star- or spindle-shaped (Fig 3B), but most of the differen-
tiated SU-2 cells were round or oval (Fig 3E). Fluores-
cence-activated cell sorting confirmed the presence of
CD133+ cells. The relative content of CD133+ cells was
markedly higher in the recurrent cell line SU-2 (8.1%, Fig
3F) than in the primary tumor cell line SU-1 (2.0%, Fig
Culture of SU-1 and SU-2 cells in vitro Figure 3
Culture of SU-1 and SU-2 cells in vitro. A, tumor sphere of SU-1 (250×). B, differentiated SU-1 (100×). C, percentage of 
CD133+ SU-1 cells detected by FCM. D, tumor sphere of SU-2 (250×). E, differentiated SU-2 cells (250×). F, percentage of 
CD133+ SU-2 cells detected by FCM.BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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3C). Non-specific staining was 1.3% for SU-1 and 0.6%
for SU-2.
Intracranial xenografts derived from SU-2 are more 
aggressive than those from SU-1
When inoculated intracranially into athymic (NCR nu/
nu) mice, both SU-1 and SU-2 reproducibly established
tumors (5/5 for both SU-1 and SU-2). The average median
survival time was 32 days for SU-1 and 27 days for SU-2.
Pathologically, SU-1 cells gave rise to less invasive tumor
masses; most of the tumor was restricted to the ipsilateral
hemisphere of the injection site, and nodular tumor for-
mation was observed (Fig. 4A, 4B). In contrast, tumors
derived from SU-2 cells showed diffuse infiltrating growth
patterns; they were distinctive in that they were widely dis-
seminated, invaded the ipsilateral hemisphere, migrated
to the cortex on the contralateral side and infiltrated the
subarachnoid space of the longitudinal fissure, recapitu-
lating the original recurrent lesion (Fig. 4C). Moreover,
most tumor cells were primitive round or oval, distributed
evenly and densely without forming obvious tumor
masses, morphologically resembling gliomatosis cerebri
(Fig. 4D), indicating that the latter may be a stem cell dis-
ease. This possibility deserves further investigation.
Transmission electron microscopy showed that GSCs from 
both SU-1 and SU-2 lacked autophagosomes
Examined by transmission electron microscopy, the
nuclei of GSCs from SU-1 and SU-2 were large and regu-
lar, circular or oval in shape, with typical inner and outer
nuclear membranes, nucleopores, perinuclear space and
other structures. Euchromatin was far more abundant
than heterochromatin. Two or more nucleoli were often
observed with clear fibrillar centers (FC), dense fibrillar
components (DFC) and granular components (GC). In
the cytoplasm, ribosomes and mitochondria were abun-
dant while the Golgi apparatus and endoplasmic reticu-
lum were relatively less developed; lysosomes (including
autophagosomes) were rare in comparison with NSCs.
Taken together, these ultrastructural features implied that
the GSCs were at a primitive stage of differentiation with
low autophagic activity (Fig. 5).
Clones with altered DNA copy number identified by array-
based CGH
Among the 2621 clones spotted on the array, 2457 were
mapped to autosomes. Changes in the DNA copy number
were found in 160 clones of GSCs from SU-1 and 182
clones from SU-2. With increased resolution of the BAC
array, regions with changes in DNA copy number span-
ning more than 1 Mb could be detected in an average of
two clones. The clustered changes were defined as regions
with at least two consecutive adjacent clones within 1 Mb
on the linear map of the human genome sequence. A total
of 7 clustered regions on chromosomes 1p, 2p, 2q, 4q, 9p,
14q and 19q were identified in GSCs of both SU-1 and
SU-2 (Additional file 1). Subsequent searching of the
human genome draft revealed several prominent genes in
these regions that have often been associated with human
cancer, and these were also found to be altered (Addi-
tional file 1). Small gains or losses restricted to single BAC
clones were also detected. Most of the altered clones were
detected in GSCs from both SU-1 and SU-2. Among the
isolated BAC clones in which the tumor/normal ratio
exceeded 1.3 (gain) or was less than 0.75 (loss), a clone
on 7p12 containing the gene for epidermal growth factor
receptor (EGFR) was amplified (Figure 6A). The clone
RP11-129G17 on 10q23 had the lowest tumor/normal
ratio. Since the tumor suppressor gene PTEN is mapped
exactly to the region covered by RP11-129G17, this find-
ing suggests that PTEN was deleted in GSCs of both the
SU-1 and SU-2 lines, as has frequently been reported in
gliomas (Figure 6B). These genetic changes included dele-
tion of p18INK4 and Rb as well as the tumor suppressor
PTEN, and amplification of the oncogenes CDK7  and
EGFR. We also found some genetic changes that were
exclusive to either SU-1 or SU-2. The most intriguing of
these was the amplification of MTA 1 in SU-2 (metastasis
Pathological examination of intracranial tumor mass in NC nude mice Figure 4
Pathological examination of intracranial tumor mass in NC nude mice. A, SU-1 cells produced relatively well-delim-
ited tumor masses (HE × 20). B, local amplification of A, showing nodular tumor formation (HE × 100). C, SU-2 cells behaved 
more aggressively (HE × 20). D, SU-2 cells infiltrated remoter regions and invaded the whole brain evenly and densely (HE × 
200).BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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associated 1), a gene previously found to be closely related
to the recurrence and metastasis of breast cancer, osteosa-
rcoma and other malignances (Additional file 2).
Real-time PCR validated the results of the array-based 
CGH
To validate the array-based CGH findings, quantitative
real-time PCR was performed to examine the expression
of genes encoding EGFR,  PTEN,  CDC2  and  DNMT3B.
Consistent with the array-based CGH results, real-time
PCR showed increased expression of EGFR and DNMT3B
GSCs observed under transmission electron microscopy (TEM) showed a lack of autophagosomes Figure 5
GSCs observed under transmission electron microscopy (TEM) showed a lack of autophagosomes. A, nuclei and 
chromatin, showing a high nucleus: cytoplasm ratio, large oval nucleus and nucleoli (the asterisk indicates the FC). B, mitochon-
dria (arrow ①), Golgi apparatus (arrow ➁), rough endoplasmic reticulum (arrow ③), a couple of centrioles (arrow ④).
Copy number changes in genomic DNA from GSCs of both SU-1 and SU-2 lines were identified by the CGH array, the ideo- grams show the gains (blue) and losses (red) of DNA copy numbers Figure 6
Copy number changes in genomic DNA from GSCs of both SU-1 and SU-2 lines were identified by the CGH 
array, the ideograms show the gains (blue) and losses (red) of DNA copy numbers. Representative ratio plots of 
chromosomes 7, with amplification of oncogene EGFR (A), and 10, with deletion of tumor suppressor PTEN (B); Real-time 
quantitative PCR validated some of array-based CGH results (C).BMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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and down-regulation of PTEN and CDC2 in GSCs com-
pared to normal human NSCs (Figure 6C).
Discussion
In the past few years, stem cell-like tumor precursors have
been identified in gliomas. They have been consecutively
termed glioma stem cells, brain tumor stem cells or brain
tumor initiating cells. They are characterized by self-
renewal, limitless proliferation, tumor initiation, multi-
differentiation and expression of stem cell surface markers
such as CD133 and nestin. However, long-term stable
maintenance of GSCs, which will offer much more con-
venient opportunities for attaining full and accurate
understanding of the biological features of this special
tumor cell type, has been achieved by only a few groups
and does not suffice to meet research requirements
[18,19]. No pure CD133+ glioma stem cell line has so far
been available; proliferation and differentiation of these
tumor stem cells in vitro cannot be stopped completely
even in a culture medium favoring stem cell growth. The
percentage of CD133+ cells in such lines has varied
widely. Accordingly, there are no unanimously agreed cri-
teria for establishing a GSC line. Successful cell lines from
other tumors suggest that establishment of a GSC line
should meet the following criteria. First, GSCs can be cul-
tured long-term in vitro while maintaining relatively stable
stem cell properties. Secondly, even after long-term main-
tenance, the GSCs should recapitulate their parent or orig-
inal tumor. In the current study, SU-1 and SU-2,
respectively originating from primary and recurrent glio-
mas with malignancy progression in the same patient,
have been maintained in vitro for more than three years
while retaining their tumor stem cell properties. Though
the percentage of CD133+ cells was not high (less than
10%), nestin+ cells were the dominant subgroup (> 90%).
Thus, the two newly established cell lines SU-1 and SU-2
could be regarded as glioma stem/progenitor lines. Cryo-
preservation and resuscitation were successful during
long-term serial passages in vitro. We also noticed differ-
ences in configuration between the tumor spheres derived
from SU-1 and SU-2. When cultured in defined stem cell
growth medium (FBS free), the SU-1 spheres were more
compact than those of SU-2, and the percentage of
CD133+ cells was lower. When cultured in serum-based
medium, SU-2 seemed more resistant to FBS-induced dif-
ferentiation and remained more morphologically primi-
tive than SU-1. In vivo, direct orthotopic transplantation
of SU-1 and SU-2 cells developed into xenografts in
immune-deficient mouse cerebrum, but the tumors
derived from SU-2 cells were more aggressive than those
from SU-1. These data imply that malignancy progression
could also occur in tumor stem cells. Taken together, these
results suggest that SU-1 and SU-2 could provisionally be
regarded as permanent glioma stem/progrnitor cell lines
and further utilized as reliable resources for basic research
and clinical trials concerning GSCs.
The study of GSCs is actually an extension of that of NSCs,
since not only the concepts but also the methods
employed are derived from those used for NSCs. The find-
ing that 102 CD133+ tumor cells could produce tumor
mass in NOD-SCID mice, while up to 105 CD133- tumor
cells could not, proved that the former were brain tumor
initiating cells and the latter were not [8]. So it seemed
reasonable to suppose that CD133+ tumor stem cells
could proliferate and differentiate into CD133- cells,
which could further differentiate into common tumor
cells approaching terminal differentiation, as NSCs do.
However, Beier's studies revealed that four of 15 cell lines
derived from primary glioblastomas grew adherently in
vitro and were driven by CD133- tumor cells that fulfilled
stem cell criteria. Both CD133+ and CD133- subtypes of
GSCs were similarly tumorigenic in nude mice in vivo
[20], indicating that CD133 expression is not sufficient to
identify GSCs; more effort is needed to identify a specific
GSC marker. At present, though this functional criterion
for GSCs is sophisticated and inconvenient to apply, it is
reliable and should not be neglected unless and until a
specific marker for GSCs is found.
GSCs do not differentiate terminally under conditions
that would induce terminal differentiation in NSCs. Not
only was differentiation retarded, but retro-differentiation
was also observed in vitro. Our data showed that soon after
treatment with differentiation-inducing agents such as
FBS and valproate (VPA), nonadherent tumor spheres dis-
sociated and scattered into adherent spindle-shaped mon-
olayer cells. Most of these were still highly positive for
nestin (a marker for neural stem/progenitor cells), while a
few cells appeared that were doubly positive for nestin
and either GFAP (marker for astrocytes) or β-tubulin III
(marker for neurons). Markers of both mature and stem/
progenitor cells are very rarely co-expressed during NSC
differentiation, but it is common in GSCs [15]. We also
observed a "down-up" trend in the percentages of
CD133+ cells in SU-1 and SU-2 during a relatively long
differentiation-inducing process in vitro; that is, the per-
centage of CD133+ cells decreased at first, then remained
low for a time and finally increased a little, suggesting that
partially differentiated CD133+ cells (loss of CD133
expression) retro-differentiated into CD133+ GSCs under
certain circumstances, which made the GSCs involved in
tumor remodeling more sophisticated. There was a con-
comitant "up-down" trend in the levels of the neural dif-
ferentiation markers GFAP and β-tubulin-III. These
phenomena were more obvious in SU-2 [15]. Thus, it is
easy to infer that GSCs were generally similar to NSCs but
showed important differences. Under conditions in which
differentiation would be induced in NSCs, GSCs showedBMC Cancer 2008, 8:304 http://www.biomedcentral.com/1471-2407/8/304
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an intrinsic potential to maintain their undifferentiated
state or to resist differentiation and even tended to retro-
differentiate under certain circumstances. Once differenti-
ation was initiated in NSCs, they were transformed step by
step into various kinds of mature neural cells.
Amplification of the oncogene EGFR and deletion of the
tumor suppressor PTEN have been identified as the criti-
cal genetic changes in the tumorigenesis of human GBMs
or other types of glioma. However, few existing glioma
cell lines harbor these genetic abnormalities [21-32]. The
fact that GSCs of both the SU-1 and SU-2 lines faithfully
preserved the EGFR amplification and PTEN loss greatly
enhances their utility in biological and preclinical studies
of human gliomas. Recent studies have shown a close cor-
relation between PTEN loss and low autophagic activiy
[33]. We also found that PTEN  loss and absence of
autophagy were concurrent in both SU-1 and SU-2, and
this may suggest potential targets for future molecular
intervention. More intriguingly, we discovered amplifica-
tion of MTA1 in SU-2 but not in SU-1. MTA1 is closely
associated with various malignancies and its up-regula-
tion always indicates tumor recurrence and metastasis
[34-39]. However, the significance of MTA1 in the malig-
nancy progression of gliomas has rarely been considered.
In the current study, the particular amplification of MTA1
in GSCs derived from the recurrent tumor makes it rea-
sonable to conjecture that MTA1 activation may contrib-
ute to both the aggression of GSCs and the malignancy
progression of gliomas.
Conclusion
In summary, we successfully established two glioma stem/
progenitor cell lines from primary and recurrent tumors
with malignancy progression obtained from the same
patient. We discovered that GSCs in the recurrent tumor
with malignancy progression were more aggressive than
in the primary tumor, which suggests that tumor progres-
sion may be initiated early in tumor stem cells. We also
demonstrated that direct isolation and long term mainte-
nance of GSCs from freshly resected glioma tissues is a fea-
sible approach for future biological studies of cancer stem
cells and pre-clinical testing of novel therapeutic agents.
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